Medicinal iatrogenics in hospitals: A survey on a given day;Iatrogénie médicamenteuse è l'hôpital: Enquête un jour donné

Presse Medicale

Volumn 32, Issue 15, 2003, Pages 683-688

  Baune, B ^a   Kessler, V ^a   Patris, S ^b   Descamps, V ^a   Casalino, E ^a   Quenon, J L ^b   Farinotti, R ^a  

^a BICHAT HOSPITAL   (France)

^b Faculté Xavier Bichat   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; DISEASE SEVERITY; FRANCE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; IATROGENIC DISEASE; MAJOR CLINICAL STUDY; PRESCRIPTION; RISK MANAGEMENT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; DATA COLLECTION; FEMALE; HOSPITALIZATION; HOSPITALS; HUMANS; IATROGENIC DISEASE; LENGTH OF STAY; LINEAR MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PARIS; PHARMACEUTICAL PREPARATIONS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0038415812     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Imbs JL, Pouyanne P, Haramburu F et al. Iatrogénie médicamenteuse: estimation de sa prévalence dans les hõpitaux publics français. Thérapie 1999; 54: 21-27.
2. Bates DW, Cullen DJ, Laird N et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1999; 274: 29-34.
3. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-11.
4. Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol 2001; 56: 935-41.
5. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke J. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
6. Pouyanne P, Haramburu F, Imbs JL, Begaud B. Admission to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres. BMJ 2000; 320: 1036.
7. Queneau P, Chabot JM, Rajaana H, Boissier C, Grandmottet P. Iatrogénie observée en milieu hospitalier. L. À propos de 109 cas colligés à partir d'une enquête transversale de I'APNET. Bull Acad Natl Med 1992; 176: 511-26.
8. Lazarou J, Pomeranz BH, Corey P. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.
9. Schermock GT, Thornton J.-P. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538.
10. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Thérapie 1985; 40: 111-8.
11. Leape LL, Brennan TA, Laird N et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991 7; 324: 377-84.
12. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-8.
13. Gholami K, Shalviri G. Factors associated with preventability, predictability and severity of adverse drug reactions. Ann Pharmacother 1999; 33: 236-40.
14. Senst BL, Achusim LE, Genest RP et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001; 58: 1126-32.